PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events:
2024 Wells Fargo Healthcare Conference
| • | Management will host one-on-one investor meetings on Wednesday, September 4, 2024, at the Encore Boston Harbor Hotel in Boston. |
2024 Morgan Stanley 22nd Annual Global Healthcare Conference
| • | Management will host a fireside session on Thursday, September 5, 2024, at 2:35 p.m. Eastern Time (ET) at the Marriott Marquis in New York. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at https://investors.embecta.com. |
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships, and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, Instagram and Twitter.
Contacts:
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$10.53 |
| Daily Change: | 0.07 0.67 |
| Daily Volume: | 747,076 |
| Market Cap: | US$612.110M |
February 06, 2025 September 03, 2024 August 09, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
